Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lydia Brugel-Ribere"'
Autor:
André Coste, Céline Croce, Daniel Isabey, Michel Rugina, Christrian Larger, Redouane Fodil, Lydia Brugel-Ribere, Jean-François Papon, Bruno Louis, Françoise Zerah-Lancner
Publikováno v:
Journal of Applied Physiology. 100:107-111
Nasal compliance is a measure related to the blood volume in the nasal mucosa. The objective of this study was to better understand the vascular response in vasomotor rhinitis by measuring nasal cross-sectional area and nasal compliance before and af
Autor:
Robert C. Kern, Jean-Yves Guillaume, Lydia Brugel-Ribere, Peter Doble, Mihail Dan Rugina, Roger Peynegre, Jean-François Papon, André Coste
Publikováno v:
Otolaryngology–Head and Neck Surgery. 137
Autor:
Céline Croce, Gabriela Sbirlea-Apiou, Daniel Isabey, Christian Larger, Christophe Delclaux, André Coste, Redouane Fodil, Bruno Louis, Jean-François Papon, Lydia Brugel-Ribere
Publikováno v:
Journal of applied physiology (Bethesda, Md. : 1985). 98(1)
We have developed a discrete multisegmental model describing the coupling between inspiratory flow and nasal wall distensibility. This model is composed of 14 individualized compliant elements, each with its own relationship between cross-sectional a
Autor:
Daniel Isabey, André Coste, Alain Harf, Bruno Louis, Redouane Fodil, Lydia Brugel-Ribere, Christian Larger
Publikováno v:
Journal of applied physiology (Bethesda, Md. : 1985). 93(1)
To explore the determinants of possible collapse of the nasal valve region, a common cause of nasal obstruction, we evaluated the mechanical properties of the nasal wall. In this study, we determined the nasal cross-sectional area-to-negative pressur
Autor:
Yoann Pointreau, Jérôme Fayette, Lydia Brugel Ribere, Isabelle Tennevet, Anne-Françoise Dillies, Sylvie Zanetta, Joseph Kerger, Laurence Bozec Le Moal, Christian Sire, Stefanie Henry, Jean-Pascal Machiels, Stéphane Temam, Gortec, Joël Guigay
Publikováno v:
Journal of Clinical Oncology. 30:5505-5505
5505 Background: Cetuximab in combination with platinum and 5FU (PFEx) has become a standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane combinations have shown promising activity. This multicenter phase II study ev